ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada2026
Prescribing patterns and impact of glucagon-like peptide-1 receptor agonists in a kidney transplant evaluation cohort in British Columbia, Canada A single-center experience.
Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGlucagon-like peptide-1 receptor agonists (GLP-1RA) have demonstrated weight loss and cardiometabolic benefits in specific subpopulations. Studies of GLP-1RAs in Canadian end-stage renal disease (ESRD) and kidney transplantation (KT) patients are limited.
methodsThis is a retrospective cohort study of patients evaluated for potential KT at the Vancouver General Hospital (VGH) between January 2014 and August 2024. We analyzed prescription patterns, weight changes, and post-transplant outcomes.
resultsAt evaluation, 63/2789 (2.3%) patients were on a GLP-1RA. The proportion of GLP-1RA users increased from 0% in 2014-2018, to 0.3% (1/366) in 2019, and 8.7% (20/231) in 2024. There was a mean weight change of -1.82 kg (-1.93%, 95% confidence interval [CI] -3.46 to -0.19, p=0.031; n=26) at six months and -2.50 kg (-2.62%, 95% CI -4.47 to -0.52, p=0.016; n=25) at 12 months post-initiation. Twenty-six patients received a KT and had a median followup of 1.14 (interquartile range [IQR] 0.19-1.79) years. Only 11 patients were on a GLP-1RA at one year post-transplant and had available post-transplant outcome data. No significant differences were detected in estimated glomerular filtration rate (eGFR) (67, IQR 65.5-78 vs. 59, IQR 45-75 mL/min/1.73 m
conclusionsGLP-1RA use in BC's KT evaluation cohort increased since 2019 and was associated with modest weight loss at six and 12 months post-initiation. No significant differences in post-transplant outcomes were detected. This provides preliminary support for GLP-1RAs as a potentially safe weight management strategy for Canadian KT candidates.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.